Clinical trials: Cognitive Function Decline
Postoperative Delirium, Postoperative Pain
Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain
This will be a double blind, placebo-controlled study of patients ≥65 years of age undergoing surgery of the spine, hips and knees replacement at the University of California, San Francisco (UCSF) Medical Center.
- Conditions
- Postoperative Delirium, Postoperative Pain, Opioid Use, Hospital Length of Stay
- Trial name
- NCT00221338
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- University of California, San Francisco
Alzheimer Disease, Cognitive Decline
Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
The investigators will conduct tau positron emission tomography (PET) scans on 125 adults using the radiopharmaceutical Flortaucipir F18 ([18F]AV-1451).
- Trial name
- NCT04080544
- Testing
- [18F]AV-1451, Positron Emission Tomography
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Neil M Rofsky, MD, MHA
Delirium, Cognitive Decline
Early Cognitive Intervention in Delirium
This is a randomized control trial to determine if early cognitive training and rehabilitation improve 4-month cognition in hospitalized older (>=65 years old) delirious patients with and without Alzheimer's disease and related…
- Conditions
- Delirium, Cognitive Decline, Dementia
- Trial name
- ECID (NCT04740567)
- Testing
- Cognitive Training, Goal Management Training
- Where
- 2 sites in United States
- Volunteers
- 283 people
- Sponsor
- Vanderbilt University Medical Center
Alzheimer Disease
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of…
- Trial name
- NCT00506415
- Testing
- Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2
- Where
- 145 sites in United States, Canada and 5 more
- Volunteers
- 1,584 people
- Sponsor
- Novartis Pharmaceuticals
Dementia, Alzheimer Disease
The Healthy Patterns Sleep Study
The Healthy Patterns Study intervention is a home-based activity intervention designed to improve symptoms of circadian rhythm disorders (CRD) and quality of life (QOL) in home-dwelling persons with dementia.
- Conditions
- Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder
- Trial name
- NCT03682185
- Testing
- Attention-Control Condition, Timed Activity Intervention
- Where
- United States
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Fatigue, Musculoskeletal Pain
Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)
This study will investigate the use of adjunctive pregnenolone for the following: 1. fatigue that has limited usual activity, 2. musculoskeletal pain involving 2 or more regions of the body and, 3.
- Conditions
- Fatigue, Musculoskeletal Pain, Cognitive Decline
- Trial name
- NCT01956279
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- VA Office of Research and Development
Mild Cognitive Impairment, Cognitive Decline
Effects of Walkasins on Gait Speed of Individuals With Mild Cognitive Impairments
The primary aim of this pilot study is to investigate the effect of Walkasins, a wearable lower-limb sensory prosthesis, on the gait speed and balance function of participants with mild cognitive impairment as measured by the…
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Gait Disorders in Old Age
- Trial name
- NCT05723822
- Testing
- Walkasins
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- RxFunction Inc.
Cognitive Decline
A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids…
- Trial name
- VITAL-Cog (NCT01669915)
- Testing
- vitamin D3, omega-3 fatty acids (fish oil)
- Where
- United States
- Volunteers
- 3,424 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Cognitive Dysfunction, Cognitive Impairment
CAMCI: Advancing the Use of Computerized Screening in Healthcare
Cognitive impairment is a significant health problem in the United States, resulting in costs over $100 billion a year. We will provide an efficient, effective, and financially intelligent solution to Primary Care Physician's to…
- Conditions
- Cognitive Dysfunction, Cognitive Impairment, Cognitive Decline, Cognitive Change
- Trial name
- NCT03512301
- Testing
- CAMCI, MoCA, Clinical Adjudication
- Where
- 4 sites in United States
- Volunteers
- 773 people, healthy volunteers welcome
- Sponsor
- Psychology Software Tools, Inc.
Multiple Sclerosis, Cognitive Decline
Digital Cognition in Multiple Sclerosis
A DIGITAL THERAPEUTIC TO IMPROVE THINKING IN MULTIPLE SCLEROSIS WHO: 65 participants with a confirmed diagnosis of Multiple Sclerosis (MS) WHY: Purpose of the study is to compare the effect of 2 tablet-based brain training…
- Trial name
- DigCog (NCT03569618)
- Testing
- Tablet-based Game
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Cognitive Decline, Chemo-brain
Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer
Purpose: To conduct a one-arm phase II trial to: (1) compare changes in pre- to post-chemotherapy cognitive function in a cohort of patients with breast cancer receiving memantine to historical controls; (2) examine how…
- Trial name
- NCT04033419
- Testing
- Memantine
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cognitive Decline
An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults
The purpose of this study is to determine whether a 6 month dietary intervention with wild blueberry powder and extract stabilised with L-cysteine and L-glutathione have an effect on cognitive performance in participants aged…
- Trial name
- NCT02446314
- Testing
- Wild Blueberry Powder - 450mg, Wild Blueberry Powder - 900 mg, Wild Blueberry extract 100mg
- Where
- United Kingdom
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- University of Reading
Hypertension
Systolic Blood Pressure Intervention Trial
Elevated blood pressure (BP) is an important public health concern. It is highly prevalent, the prevalence may be increasing, and it is a risk factor for several adverse health outcomes, especially coronary heart disease, stroke…
- Trial name
- SPRINT (NCT01206062)
- Testing
- Intensive control of SBP, Standard control of SBP
- Where
- United States
- Volunteers
- 9,361 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Mild Cognitive Impairment
Effects Multimodal Mind and Body Approach for MCI
The aim of this application is to develop a computer-based multimodal mind and body approach (CMMBA) for mild cognitive impairment (MCI).
- Trial name
- NCT06814483
- Testing
- Experimental: A computer-based multimodal mind and body approach (cbMMBA), A standard cognitive training group
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Parkinson, Parkinson Disease
Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers
Every year, approximately 9,000 Parkinson disease (PD) patients undergo deep brain stimulator (DBS) placement into the subthalamic nucleus (STN-DBS).
- Conditions
- Parkinson, Parkinson Disease, Genetic Predisposition, GBA Gene Mutation
- Trial name
- NCT03234478
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Rutgers, The State University of New Jersey
Ischemic Stroke, Cerebral Small Vessel Disease
Remote Preconditioning Over Time To Empower Cerebral Tissue
Previous studies in animals and humans has shown that brief periods of reduced blood flow to one organ or tissue in the body can help protect other tissues from subsequent injury caused by reduced blood flow such as a stroke.
- Conditions
- Ischemic Stroke, Cerebral Small Vessel Disease, Cognitive Decline
- Trial name
- REM-PROTECT (NCT02169739)
- Testing
- Ischemic Preconditioning
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Los Angeles
Frontal Lobe Dementia, Frontotemporal Lobe Dementia
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
The primary objective of the study is to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia.
- Conditions
- Frontal Lobe Dementia, Frontotemporal Lobe Dementia, Semantic Dementia
- Trial name
- NCT00545974
- Testing
- memantine
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- University of California, San Francisco
Health, Subjective, Disability, Evaluation
Ageing and Health. Spanish Longitudinal Study
Ageing with Health is a longitudinal cohort study aimed to examine trajectories of health, disability and wellbeing and their determinants for Spanish ageing population.
- Conditions
- Health, Subjective, Disability, Evaluation, Chronic Disease, Mental Disorder
- Trial name
- NCT03343886
- Where
- 3 sites in Spain
- Volunteers
- 7,755 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Mild Cognitive Impairment (MCI)
Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment
The goal of this study is to determine whether increasing participation in cognitive, physical, and/or social activities prevents cognitive decline in older African Americans (AAs) with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01299766
- Testing
- Behavioral Activation (BA), Supportive Therapy (ST)
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Thomas Jefferson University
Cognitive Impairment, End Stage Renal Disease
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
This study will evaluate the tolerability, feasibility, and efficacy of the AKST1210 column in subjects with end-stage renal disease with cognitive impairment (ESRD-CI) undergoing hemodialysis 3 times per week.
- Trial name
- NCT04527328
- Testing
- AKST1210, Hemodialysis
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alkahest, Inc.